GLP1R and obesity due to melanocortin 4 receptor deficiency: In addition, whilst dietary and physical activity interventions have traditionally formed the cornerstone of obesity management, the increasing adoption of pharmacological therapies, particularly GLP-1 receptor agonists warrants scrutiny of the evolving evidence base [48], especially in adolescent populations.